Testing T-DXd combinations for HER2 stomach or esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests how safe and effective T-DXd (an anti-cancer medicine) is in combination for people with advanced stomach/GEJ/esophagus cancer that is HER2-positive or HER2-low. It may help people whose cancer has spread or cannot be removed, depending on their prior treatments and test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old
- Your cancer is adenocarcinoma of the stomach, where the esophagus meets the stomach (GEJ), or the esophagus, and it is either HER2-positive or HER2-low based on a tissue test
- Your cancer is locally advanced and cannot be removed or has spread to other parts of the body
- Your cancer has measurable tumors on scans (the study will confirm it can track changes)
- Your blood counts and organ function (heart, kidneys, liver) are in acceptable ranges
- If you can become pregnant or father a child, you will use reliable birth control during and after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies T-DXd given with ramucirumab to treat stomach (gastric) or stomach–esophagus junction (GEJ) cancer that has spread or is locally advanced and is “HER2-low.” It’s mainly to test safety and early effectiveness in people whose cancer continued after first-line treatment.
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Cetuximab, for people with colorectal cancer that has spread or cannot be removed by surgery. It is for those whose tumors have low levels of a protein called HER2 and who have already tried certain standard treatments.
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.